Rapid Systemic Delivery of Zolmitriptan Using an Adhesive Dermally Applied Microarray
Author(s) -
Donald Kellerman,
Mahmoud Ameri,
Stewart J. Tepper
Publication year - 2017
Publication title -
pain management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.402
H-Index - 21
eISSN - 1758-1877
pISSN - 1758-1869
DOI - 10.2217/pmt-2017-0036
Subject(s) - zolmitriptan , medicine , sumatriptan , pharmacokinetics , migraine , pharmacology , rizatriptan , biomedical engineering , anesthesia , agonist , receptor
Adhesive Dermally-Applied Microarray (ADAM) is a device for intracutaneous drug administration consisting of a 3 cm 2 disposable array of drug-coated titanium microprojections on an adhesive backing. It is applied using a low cost, reusable, handheld applicator. Microprojections penetrate the stratum corneum, delivering drug proximal to capillaries with limited likelihood of pain. The pharmacokinetics of zolmitriptan delivery using ADAM was evaluated in 20 healthy volunteers. Median t max was <20 min, comparable to subcutaneous sumatriptan. Absorption was faster than for oral zolmitriptan, with higher exposure in the first 2 h. Most adverse events were consistent with those seen in previous triptan trials. Application site reactions were generally mild and resolved within 24 h. ADAM zolmitriptan shows a promising pharmacokinetic profile for migraine treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom